It has been posited that the beneficial actions of SGLT2 inhibitors on cardiovascular outcomes in T2D are dependent on increases in cardiac ketone oxidation, though this remains an ongoing topic of debate (Lopaschuk & Verma, 2020; Packer, 2023). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.